4-(4-formyl-2-methoxyphenoxy)naphthalene-1-carbonitrile | 1055361-84-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-formyl-2-methoxyphenoxy)naphthalene-1-carbonitrile
• 英文别名: 4-(4-formyl-2-methoxyphenoxy)naphthalene-l-carbonitrile
• CAS: 1055361-84-6
• 化学式: C₁₉H₁₃NO₃
• 分子量: 303.317
• InChiKey: YTFYDPWYEZIENS-UHFFFAOYSA-N

物化性质

• 沸点：
  512.4±45.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-formyl-2-methoxyphenoxy)naphthalene-1-carbonitrile 在 盐酸 、 potassium tert-butylate 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.5h， 生成 4-{4-[(Z)-(4-amino-2-oxo-1,3-thiazol-5(2H)-ylidene)methyl]-2-methoxyphenoxy}naphthalene-1-carbonitrile
  参考文献：
  名称：

  EP2450352

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氟萘-1-甲腈 、 香草醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以86%的产率得到4-(4-formyl-2-methoxyphenoxy)naphthalene-1-carbonitrile
  参考文献：
  名称：

  Identification of Diaryl Ether-Based Ligands for Estrogen-Related Receptor α as Potential Antidiabetic Agents

  摘要：

  Estrogen-related receptor a (ERR alpha) is an orphan nuclear receptor that has been functionally implicated in the regulation of energy homeostasis. Herein is described the development of diaryl ether based thiazolidenediones, which function as selective ligands against this receptor. Series optimization provided several potent analogues that inhibit the recruitment of a coactivator peptide fragment in in vitro biochemical assays (IC50 < 150 nM) and cellular two-hybrid reporter assays against the ligand binding domain (IC50 = 1-5 mu M). A cocrystal structure of the ligand-binding domain of ERR alpha with lead compound 29 revealed the presence of a covalent interaction between the protein and ligand, which has been shown to be reversible. In diet-induced murine models of obesity and in an overt diabetic rat model, oral administration of 29 normalized insulin and circulating triglyceride levels, improved insulin sensitivity, and was body weight neutral. This provides the first demonstration of functional activities of an ERRa ligand in metabolic animal models.

  DOI：

  10.1021/jm101063h

文献信息

• SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS
  申请人：Gaul Michael

  公开号：US20090111855A1

  公开（公告）日：2009-04-30

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式（I）化合物，制备这些化合物的方法、组合物、中间体和衍生物，用于治疗包括但不限于强直性脊柱炎、动脉粥样硬化、关节炎（如类风湿性关节炎、感染性关节炎、儿童关节炎、银屑病性关节炎、反应性关节炎）、骨相关疾病（包括与骨形成有关的疾病）、乳腺癌（包括对抗雌激素治疗无效的乳腺癌）、心血管疾病、软骨相关疾病（如软骨损伤/丢失、软骨退化和与软骨形成有关的疾病）、软骨发育不良、软骨肉瘤、慢性背部损伤、慢性支气管炎、慢性炎性气道疾病、慢性阻塞性肺疾病、糖尿病、能量稳态紊乱、痛风、假性痛风、脂质代谢紊乱、代谢综合征、多发性骨髓瘤、肥胖症、骨关节炎、成骨不全症、骨转移性溶骨性肿瘤、软骨软化症、骨质疏松症、帕吉特病、牙周病、多肌痛风和Reiter综合征、重复性应力损伤、高血糖、血糖水平升高和胰岛素抵抗等疾病。
• Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators
  申请人：Janssen Pharmaceutica, NV

  公开号：US07846953B2

  公开（公告）日：2010-12-07

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨有关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丢失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态障碍，痛风，假性痛风，脂质代谢紊乱，代谢综合症，多发性骨髓瘤，肥胖症，骨关节炎，成骨不全症，骨溶解性骨转移，软骨软化症，骨质疏松症，帕吉特病，牙周病，多肌病性风湿病，Reiter综合症，重复性应力损伤，高血糖，血糖水平升高和胰岛素抵抗等疾病。
• PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER
  申请人：Hasuoka Atsushi

  公开号：US20120196864A1

  公开（公告）日：2012-08-02

  A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has a superior activity as an estrogen-related receptor-α modulator, and is useful as a prophylactic or therapeutic agent for cancer.

  化合物的化学式为（I）：其中每个符号如规范中所述，或其盐具有优越的活性作为雌激素相关受体-α调节剂，并且可用作预防或治疗癌症的药物。
• SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-á MODULATORS
  申请人：Gaul Michael

  公开号：US20110237625A1

  公开（公告）日：2011-09-29

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式（I）化合物，制备这些化合物的方法，组成物，中间体和衍生物，用于治疗包括但不限于强直性脊柱炎，动脉硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），骨相关疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的乳腺癌），心血管疾病，软骨相关疾病（如软骨损伤/缺失，软骨退化，以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性背部受伤，慢性支气管炎，慢性炎性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态失调疾病，痛风，假性痛风，脂质代谢紊乱，代谢综合征，多发性骨髓瘤，肥胖症，骨关节炎，骨发育不全，骨转移性溶骨性转移，软骨软化症，骨质疏松症，Paget病，牙周疾病，多肌痛性风湿病，Reiter综合征，重复应力损伤，高血糖，血糖水平升高和胰岛素抵抗等症状。
• Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators
  申请人：Janssen Pharmaceutica, NV

  公开号：US08344009B2

  公开（公告）日：2013-01-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式（I）化合物、制备这些化合物的方法、组合物、中间体和衍生物，用于治疗包括但不限于强直性脊柱炎、动脉粥样硬化、关节炎（如类风湿性关节炎、感染性关节炎、儿童关节炎、银屑病性关节炎、反应性关节炎）、与骨相关的疾病（包括与骨形成相关的疾病）、乳腺癌（包括对抗雌激素治疗无效的乳腺癌）、心血管疾病、软骨相关疾病（如软骨损伤/丧失、软骨退化、与软骨形成相关的疾病）、软骨发育不良、软骨肉瘤、慢性背部损伤、慢性支气管炎、慢性炎性气道疾病、慢性阻塞性肺疾病、糖尿病、能量稳态失调疾病、痛风、假性痛风、脂质代谢紊乱、代谢综合征、多发性骨髓瘤、肥胖症、骨关节炎、成骨不全症、骨转移性溶骨性肿瘤、佝偻病、骨质疏松症、帕吉特病、牙周病、多肌痛性类风湿、Reiter综合征、重复性应力损伤、高血糖、升高的血糖水平和胰岛素抵抗等疾病。